For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Novavax, Inc (NASDAQ: NVAX) closed at $6.76 in the last session, up 2.27% from day before closing price of $6.61. In other words, the price has increased by $2.27 from its previous closing price. On the day, 5.45 million shares were traded. NVAX stock price reached its highest trading level at $6.9 during the session, while it also had its lowest trading level at $6.52.
Ratios:
We take a closer look at NVAX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.03 and its Current Ratio is at 2.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on June 17, 2025, initiated with a Sell rating and assigned the stock a target price of $6.
On February 28, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $19.
JP Morgan Downgraded its Neutral to Underweight on July 30, 2024, while the target price for the stock was maintained at $8.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 19 ’25 when YOUNG JAMES F bought 10,000 shares for $7.59 per share.
YOUNG JAMES F bought 4,000 shares of NVAX for $24,406 on Apr 14 ’25. On Dec 13 ’24, another insider, King Rachel K., who serves as the Director of the company, sold 4,150 shares for $9.02 each. As a result, the insider received 37,435 and left with 14,770 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 1094917248 and an Enterprise Value of 517593120. As of this moment, Novavax,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2.55, and their Forward P/E ratio for the next fiscal year is 29.79. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.87. Its current Enterprise Value per Revenue stands at 0.412 whereas that against EBITDA is 1.107.
Stock Price History:
The Beta on a monthly basis for NVAX is 2.49, which has changed by -0.43193275 over the last 52 weeks, in comparison to a change of 0.1185931 over the same period for the S&P500. Over the past 52 weeks, NVAX has reached a high of $17.81, while it has fallen to a 52-week low of $5.01. The 50-Day Moving Average of the stock is -0.05%, while the 200-Day Moving Average is calculated to be -20.04%.
Shares Statistics:
According to the various share statistics, NVAX traded on average about 9.01M shares per day over the past 3-months and 4982240 shares per day over the past 10 days. A total of 161.96M shares are outstanding, with a floating share count of 147.54M. Insiders hold about 8.91% of the company’s shares, while institutions hold 56.79% stake in the company. Shares short for NVAX as of 1749772800 were 44482397 with a Short Ratio of 4.94, compared to 1747267200 on 46467707. Therefore, it implies a Short% of Shares Outstanding of 44482397 and a Short% of Float of 27.560000000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
